From transformative genetic therapies in rare diseases to neuroimmunology candidates addressing residual unmet needs in MS, and novel target validation driving confidence in disease modification for neurodegeneration, best- and first-in-class neuroscience opportunities continue to shape and drive pharma investment.

Prices: USD 2699.00 – USD 6498.00

Time: 8:00 am to 3:00 pm

Speakers: Murali Gopalakrishnan, Global Head, Neuroscience Search and Evaluation, Corporate Strategy, AbbVie and more

Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States